ATE272719T1 - Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen - Google Patents

Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen

Info

Publication number
ATE272719T1
ATE272719T1 AT95904188T AT95904188T ATE272719T1 AT E272719 T1 ATE272719 T1 AT E272719T1 AT 95904188 T AT95904188 T AT 95904188T AT 95904188 T AT95904188 T AT 95904188T AT E272719 T1 ATE272719 T1 AT E272719T1
Authority
AT
Austria
Prior art keywords
ligand
dna
receptor
receptors
drugs
Prior art date
Application number
AT95904188T
Other languages
English (en)
Inventor
Lawrence B Hendry
Original Assignee
Lawrence B Hendry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lawrence B Hendry filed Critical Lawrence B Hendry
Application granted granted Critical
Publication of ATE272719T1 publication Critical patent/ATE272719T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Computing Systems (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Library & Information Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT95904188T 1993-11-26 1994-11-28 Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen ATE272719T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15868993A 1993-11-26 1993-11-26
PCT/US1994/013765 WO1995014791A1 (en) 1993-11-26 1994-11-28 Design of drugs involving receptor-ligand-dna interactions

Publications (1)

Publication Number Publication Date
ATE272719T1 true ATE272719T1 (de) 2004-08-15

Family

ID=22569263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95904188T ATE272719T1 (de) 1993-11-26 1994-11-28 Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen

Country Status (8)

Country Link
US (5) US5705335A (de)
EP (1) EP0740708B1 (de)
JP (1) JPH09505603A (de)
AT (1) ATE272719T1 (de)
AU (1) AU1297995A (de)
CA (1) CA2177388A1 (de)
DE (1) DE69433935D1 (de)
WO (1) WO1995014791A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933366B2 (en) * 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6040137A (en) * 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US5978740A (en) * 1995-08-09 1999-11-02 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them
CA2244228A1 (en) 1996-01-22 1997-07-24 Creative Biomolecules, Inc. Morphogen analogs and methods for producing them
US6528271B1 (en) 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
ATE219847T1 (de) 1997-09-05 2002-07-15 Accelrys Inc Interaktionsmodellierung mit atomaren parametern und anisotropischer dipol-polarisierbarkeit
EP1034188B1 (de) * 1997-11-27 2006-06-07 Commonwealth Scientific And Industrial Research Organisation Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
AU3901099A (en) * 1998-05-12 1999-11-29 Isis Pharmaceuticals, Inc. Characterization of interactions between molecular interaction sites of rna and ligands therefor
AUPP380498A0 (en) * 1998-05-29 1998-06-25 Biomolecular Research Institute Limited Egf receptor agonists and antagonists
US6542858B1 (en) 1998-09-14 2003-04-01 Lion Bioscience Ag Pharmacokinetic-based drug design tool and method
KR100303263B1 (ko) * 1998-10-13 2001-12-01 조양호 벡터를이용한rna분자이차구조의시각화방법
US6298259B1 (en) 1998-10-16 2001-10-02 Univ Minnesota Combined magnetic resonance imaging and magnetic stereotaxis surgical apparatus and processes
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6343257B1 (en) * 1999-04-23 2002-01-29 Peptor Ltd. Identifying pharmacophore containing combinations of scaffold molecules and substituents from a virtual library
US6969763B1 (en) 1999-05-12 2005-11-29 Isis Pharmaceuticals, Inc. Molecular interaction sites of interleukin-2 RNA and methods of modulating the same
US20030083483A1 (en) * 1999-05-12 2003-05-01 Ecker David J. Molecular interaction sites of vimentin RNA and methods of modulating the same
AU2001250955A1 (en) * 2000-03-23 2001-10-03 California Institute Of Technology Method and apparatus for predicting ligand binding interactions
WO2002041184A1 (fr) * 2000-11-14 2002-05-23 Kyorin Pharmaceutical Co., Ltd. Procede de recherche d'un nouveau compose tete de serie
SV2003000753A (es) * 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
DE60132815D1 (de) 2000-12-09 2008-03-27 Univ California Röntgenkristallstruktur mit 5.5 a auflösung von funktionalen komplexen des bakteriellen ribosoms, beinhaltend transfer-rna und modell boten-rna
US20030162219A1 (en) * 2000-12-29 2003-08-28 Sem Daniel S. Methods for predicting functional and structural properties of polypeptides using sequence models
US20030013137A1 (en) * 2001-03-13 2003-01-16 Barak Larry S. Automated methods of detecting receptor activity
WO2002087505A2 (en) * 2001-04-27 2002-11-07 The General Hospital Corporation 3-structure of a whole integrin $g(a)v$g(b)3 extracellular region and uses therefor
US20040002052A1 (en) * 2001-10-23 2004-01-01 Hendry Lawrence B. Systems and methods for rapid evaluation and design of molecules for predicted biological activity
WO2003051174A2 (en) * 2001-11-09 2003-06-26 Neurogenetics, Inc. Single nucleotide polymorphisms and mutations on alpha-2-macroglobulin
US20040067512A1 (en) * 2001-11-09 2004-04-08 Neurogenetics, Inc. Single nucleotide polymorphisms and mutations on Alpha-2-Macroglobulin
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US7590517B2 (en) * 2002-05-28 2009-09-15 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
WO2004035789A1 (en) 2002-10-18 2004-04-29 Lg Life Sciences Ltd. Gene families associated with cancers
JP4599292B2 (ja) 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
EP2230249A3 (de) 2003-02-06 2010-12-22 ChronTech Pharma AB Antigen/Antikörper oder Ligand/Rezeptor glycosylierter Spezifität Austauscher
US7335359B2 (en) * 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
EP1638581A2 (de) * 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Zwitterionische immunomodulatorem zur behandlung von asthma und allergien
WO2006002299A2 (en) * 2004-06-22 2006-01-05 Sarnoff Corporation Method and apparatus for recognizing 3-d objects
US20060052943A1 (en) * 2004-07-28 2006-03-09 Karthik Ramani Architectures, queries, data stores, and interfaces for proteins and drug molecules
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
KR100954322B1 (ko) 2006-06-14 2010-04-21 주식회사 엘지생명과학 췌장암과 관련된 신규한 ｌｂｆｌ313 유전자
US20090092631A1 (en) * 2007-03-26 2009-04-09 Tripep Ab Glycosylated specificity exchangers that induce an antibody dependent cellular cytotoxicity (adcc) response
WO2008154456A2 (en) * 2007-06-06 2008-12-18 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
WO2009009493A2 (en) 2007-07-09 2009-01-15 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Aegyptin and uses thereof
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
EP2731617A4 (de) 2011-07-12 2015-07-01 Brigham & Womens Hospital Lipidhaltige psa-zusammensetzungen, verfahren zu ihrer isolierung und verwendungsverfahren dafür
CN102798708A (zh) * 2012-08-23 2012-11-28 中国科学院长春应用化学研究所 一种检测配体与靶标结合特异性的方法及药物筛选方法
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461619A (en) * 1981-12-29 1984-07-24 Medical College Of Georgia Research Inst. Method of predicting biological activity of compounds by nucleic acid models
US4705796A (en) * 1986-08-25 1987-11-10 Stereochemical Genetics, Inc. Use of 3-N-phenylacetylamino-2,6-piperidinedione for treatment of neuropsychiatric disorders
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
WO1991016309A1 (en) * 1990-04-12 1991-10-31 University Of Georgia Research Foundation, Inc. Synthetic piperidinediones with cytostatic activity
US5238947A (en) * 1990-04-12 1993-08-24 University Of Georgia Research Foundation, Inc. Synthetic piperidinediones with cytostatic activity

Also Published As

Publication number Publication date
US6306595B1 (en) 2001-10-23
CA2177388A1 (en) 1995-06-01
US20020064790A1 (en) 2002-05-30
US5888741A (en) 1999-03-30
EP0740708B1 (de) 2004-08-04
AU1297995A (en) 1995-06-13
JPH09505603A (ja) 1997-06-03
DE69433935D1 (de) 2004-09-09
EP0740708A1 (de) 1996-11-06
WO1995014791A1 (en) 1995-06-01
US5705335A (en) 1998-01-06
US5888738A (en) 1999-03-30
EP0740708A4 (de) 1999-12-01

Similar Documents

Publication Publication Date Title
ATE272719T1 (de) Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen
DeMarzo et al. Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein.
BG105856A (en) Use of hydroxymatairesinol in cancer prevention
DE69627031T2 (de) Dateiprozessor für die verteilung von multimedia-dateien
EP0776331A4 (de) Struktur höherer ordnung und bindung von peptidnukleinsäuren
WO2001027857A3 (en) Methods for generating databases and databases for identifying polymorphic genetic markers
Nakajima et al. Effect of pancreatic type phospholipase A2 on isolated porcine cerebral arteries via its specific binding sites
Valentin-Opran et al. Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells.
IL163125A (en) Two tier paste buffer and display
EP1090294A4 (de) Verfahren um die anwesenheit von krebs in einer probe zu bestimmen durch nachweis der expression eines ssx-gens und peptiden, die von ssx oder ny-eso-1 abgeleitet sind
WO2004088509A3 (en) Apparatus, system and method of appending a group of files to files on a clipboard of a desktop
Chang et al. Rapid diagnosis of the HLA-H gene Cys 282 Tyr mutation in hemochromatosis by polymerase chain reaction—a very rare mutation in the Chinese population
EP1069050A3 (de) Klammer
Socher et al. Distribution of binding sites for the progesterone receptor within chick oviduct chromatin
Brotherton et al. Binding of HMG 17 to mononucleosomes of the avian β-globin gene cluster in erythroid and non-erythroid cells
von Depka et al. Altered Angiogenic Gene Expression Profiles in Porcine Von Willebrand Disease
EP1319089A4 (de) In vitro testverfahren zur bestimmung der immunogenizität eines impfstoffes
Ittel et al. DNA-poly (ADP-ribose) polymerase complex: isolation of the DNA wrapping the enzyme molecule
Veselá-Prenosilová Zapiski janycara (Book Review)
Slagter et al. Serum and urine tissue kallikrein concentrations in male-to-female transsexuals treated with antiandrogens and estrogens
Palmiter et al. KINETICS OF OVALBUMIN AND CONALBUMIN mRNA INDUCTION BY ESTROGEN AND PROGESTERONE
Thottassery Mirex-induced adaptive liver growth: Studies on glucocorticoid receptors and growth-related genes.
Song Mixing visual and textual programming in a functional language.
Ziedonis et al. Depression in Cocaine Abusing Opioid Addicts Treated with Either Buprenorphine or Methadone
Guillaume Prestwich Patricia E., Drink and the politics of social reform. Antialcoholism in France since 1870

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties